Moderna received its fifth recent institutional rating increase after positive Phase 3 results for its personalized melanoma mRNA vaccine, intismeran autogene, sent shares up 177% in one session. Argus Research upgraded the stock from Hold to Buy and set a $180 price target. The trial enrolled 1,137 patients and met its primary and key secondary endpoints, but most analysts remain cautious: Bloomberg data shows five Buy ratings, 16 Hold ratings and two Sell ratings. Moderna reported second-quarter 2026 revenue of $145 million and a GAAP net loss of $782 million, while targeting cash-flow breakeven by 2028. Investors are awaiting detailed Phase 3 data, regulatory developments, evidence that personalized manufacturing can scale economically and results from other oncology programs. At the August 26 close of $149.66, the company had an approximately $60 billion market capitalization, despite continuing financial, manufacturing, regulatory and potential dilution risks.